Form 4: Amgen SVP & CCO Nancy A. Grygiel Reports Changes in Beneficial Ownership

Nancy A. Grygiel, SVP & CCO of Amgen Inc., reports acquisition of restricted stock units and non-qualified stock options, as well as transactions in company stock through the 401(k) plan.

Summary

• Nancy A. Grygiel, SVP & CCO of Amgen Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report includes the acquisition of 591 Restricted Stock Units (RSUs) granted under the 2009 Equity Incentive Plan, vesting in four equal annual installments starting May 6, 2026.
• These RSUs include 67 Dividend Equivalents (DEs) that are credited on unvested RSUs and paid out in shares of common stock.
• Grygiel also acquired 3,824 non-qualified stock options with an exercise price of $270.44, vesting in four equal annual installments starting May 6, 2026, and expiring on May 6, 2035.
• The report also reflects shares acquired under the company's 401(k) plan.
• A disposition of common stock is reported at a price of $102.9274.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document is a standard regulatory filing detailing executive compensation. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of RSUs and stock options aligns the executive's interests with the company's long-term performance.
• Dividend Equivalents on RSUs provide additional value to the executive.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a multi-year alignment of the executive's compensation with the company's performance.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with shareholders.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and stock options, is a standard practice among publicly traded companies like Amgen to incentivize executives.
• Vesting schedules of four years are common to ensure long-term commitment.
• Companies such as Johnson & Johnson, Pfizer, and Merck also utilize similar equity compensation plans for their executives.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding executive compensation.
• The equity-based compensation structure aims to align executive interests with shareholder value.

Key Dates

Keywords

Form 4, Beneficial Ownership, Amgen, RSU, Stock Options, Grygiel, CCO, 401(k)